BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 7853807)

  • 1. [Prospects of the use of cyclosporin A in rheumatic diseases].
    Nasonov EL; Shtutman VZ; Nasonova VA
    Klin Med (Mosk); 1994; 72(5):12-9. PubMed ID: 7853807
    [No Abstract]   [Full Text] [Related]  

  • 2. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
    De Jesus A; Talal N
    Crit Care Med; 1990 Feb; 18(2 Suppl):S132-7. PubMed ID: 2298028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum complement levels in systemic lupus erythematosus].
    Morita M; Nishishita S; Amano T; Ofuji T
    Arerugi; 1971 Mar; 20(3):159-68. PubMed ID: 4101817
    [No Abstract]   [Full Text] [Related]  

  • 4. [Inflammatory rheumatism within the framework of autoimmune diseases].
    Van Slype J
    J Belge Rhumatol Med Phys; 1967; 22(4):204-7. PubMed ID: 4185872
    [No Abstract]   [Full Text] [Related]  

  • 5. [Basic immunologic indices and their significance in the diagnosis of rheumatic diseases. II. Analysis of immunologic indices in individual rheumatic diseases].
    Timofeev VT
    Revmatologiia (Mosk); 1983; (4):48-54. PubMed ID: 6366975
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
    Ebo D; DeClerck LS; Bridts CH; Stevens WJ
    In Vivo; 1994; 8(4):577-80. PubMed ID: 7534494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunology of rheumatoid diseases.
    Koffler D
    Clin Symp; 1979; 31(4):1-36. PubMed ID: 45382
    [No Abstract]   [Full Text] [Related]  

  • 8. A critical review of the effect of levamisole in rheumatic diseases other than rheumatoid arthritis.
    Rosenthal M
    J Rheumatol Suppl; 1978; 4():97-100. PubMed ID: 366146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antinuclear antibodies and beta1A concentration in systemic lupus erythematosus and other diseases].
    Monegat JN; Joller-Jemelka HI; Grob PJ
    Schweiz Med Wochenschr; 1974 Nov; 104(45):1614-23. PubMed ID: 4612703
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunology and rheumatic diseases. History and current aspects].
    Bonomo L
    Recenti Prog Med; 1976 Dec; 61(6):741-8. PubMed ID: 1088188
    [No Abstract]   [Full Text] [Related]  

  • 11. Introduction: of syndromes and interfaces.
    Ehrlich GE
    Rheumatology; 1973; 4(0):1-12. PubMed ID: 4151988
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale for T cell inhibition by cyclosporin A in major autoimmune diseases.
    Ferraccioli GF; Tomietto P; De Santis M
    Ann N Y Acad Sci; 2005 Jun; 1051():658-65. PubMed ID: 16127006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cryoglobulinemia in rheumatic diseases].
    Baranauskaĭte AA; Nasonov EL; Solov'ev SK
    Klin Med (Mosk); 1991 Jun; 69(6):23-32. PubMed ID: 1774903
    [No Abstract]   [Full Text] [Related]  

  • 14. B cell depletion therapy in rheumatic disease.
    Edwards JC; Cambridge G; Leandro MJ
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):915-28. PubMed ID: 16980214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of glucocorticosteroid and cytotoxic therapy on the natural cytotoxicity in rheumatic diseases].
    Aleksandrova EN; Nasonov EL
    Ter Arkh; 1985; 57(8):34-7. PubMed ID: 4071433
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Laboratory diagnosis of polysystemic autoimmune diseases].
    Sipka S
    Orv Hetil; 2005 Feb; 146(9):403-9. PubMed ID: 15830607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of immunosuppressive drugs: part I.
    Gerber NL; Steinberg AD
    Drugs; 1976; 11(1):14-35. PubMed ID: 770131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitory effect of sera from patients with rheumatic diseases on EA-rosette formation].
    Nasonov EL; Aleksandrova EN; Sura VV; Ivanova MM; Zimin IuI
    Ter Arkh; 1983; 55(7):32-7. PubMed ID: 6604958
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antibody-dependent and natural cellular cytotoxic reactions in rheumatic diseases].
    Aleksandrova EN; Zimin IuI; Nasonov EL
    Ter Arkh; 1984; 56(10):130-6. PubMed ID: 6084315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.